Last reviewed · How we verify
Ibandronate, Capecitabine
This combination uses ibandronate to inhibit bone resorption and capecitabine to inhibit thymidylate synthase for antitumor activity.
This combination uses ibandronate to inhibit bone resorption and capecitabine to inhibit thymidylate synthase for antitumor activity. Used for Metastatic breast cancer with bone involvement.
At a glance
| Generic name | Ibandronate, Capecitabine |
|---|---|
| Sponsor | GBG Forschungs GmbH |
| Drug class | Bisphosphonate + Fluoropyrimidine antimetabolite |
| Target | Farnesyl pyrophosphate synthase (ibandronate); Thymidylate synthase (capecitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ibandronate is a bisphosphonate that reduces osteoclast-mediated bone resorption, potentially decreasing skeletal complications and bone metastases. Capecitabine is a fluoropyrimidine carbamate prodrug that is converted to 5-fluorouracil, inhibiting thymidylate synthase and disrupting DNA synthesis in cancer cells. The combination targets both bone metastatic disease and systemic tumor burden.
Approved indications
- Metastatic breast cancer with bone involvement
Common side effects
- Nausea
- Diarrhea
- Hand-foot skin reaction
- Osteonecrosis of the jaw
- Fatigue
Key clinical trials
- Study in Elderly Patients With Early Breast Cancer (ICE) (PHASE3)
- A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |